Search
Displaying 481–490 of 645 for “retinal diseases”
-
June 21–June 22, 2024. Chicago Marriott Downtown Magnificent Mile, Chicago, Illinois. VISIONS 2024, the national conference of the Foundation Fighting Blindness, is a one-of-a-kind event in which individuals who are visually impaired, and their families, hear about exciting advancements in blindness research.
-
Research News
Clinical trial participants with advanced vision loss from RP were able to identify fruits and vegetables
-
Eye on the Cure Podcast | Episode 39: Paul Bernstein, MD, PhD
Eye on the CureJanuary 20, 2023. Paul Bernstein, MD, PhD, from the Moran Eye Center, University of Utah, and a member of the Foundation’s Scientific Advisory Board talks to host Ben Shaberman about his clinical practice for retinal disease patients
-
Luxa Doses First Participant in Clinical Trial of RPE Stem Cells for Dry AMD Patients
Research NewsThe company’s RPESC-RPE cell product is composed of progenitor-stage RPE cells grown from human eyes donated to eye banks.
-
Investigators Report Partial Vision Restoration for One Patient in Optogenetic Therapy Trial
Research NewsThe gene-agnostic approach is designed to restore some vision to people with advanced vision loss
-
Encouraging Early Report for Three Patients in LCA1-GUCY2D Gene Therapy Clinical Trial
Research NewsDevelopment of the emerging gene therapy is being funded by the Foundation’s RD Fund
-
Beacon Stories
Susan, who has retinitis pigmentosa, went through many tests in search of learning more about her eye disease. Once she enrolled in the My Retina Tracker® (MRT) testing program, Susan was provided with comprehensive results and a clear diagnosis, giving her clarity and hope.
-
Research News
Eye Bonds provide the opportunity to advance, and accelerate development for, more promising treatments into and through clinical trials and out to the people who need them.
-
About Page
Roster of the Foundation Fighting Blindness Scientific Advisory Board
-
Research News
Applied Genetic Technologies Corporation (AGTC), a leading developer of gene therapies, has reported the six-month follow-up data in all patients treated with its gene therapy for X-linked retinoschisis (XLRS) in its Phase I/II clinical trial.
.png)
